Quinolones: Review of psychiatric and neurological adverse reactions

Drug Safety

Volumn 34, Issue 6, 2011, Pages 465-488

  Tomé, Ana M ^a   Filipe, Augusto ^a  

^a Tecnimede Group   (Portugal)

Author keywords

Balofloxacin; Cinoxacin; Ciprofloxacin; Clinafloxacin; Enoxacin; Fluoroquinolones; Garenoxacin; Gatifloxacin; Gemifloxacin; Levofloxacin; Lomefloxacin; Moxifloxacin; Nadifloxacin; Nalidixic acid; Neurological disorders; Norfloxacin; Ofloxacin; Pazufloxacin; Pefloxacin; Prulifloxacin; Psychiatric disorders; Quinolones; Rufloxacin; Sitafloxacin; Sparfloxacin; Temafloxacin; Tosufloxacin

Indexed keywords

ALATROFLOXACIN; BALOFLOXACIN; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NADIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PAZUFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; PIROMIDIC ACID; PRULIFLOXACIN; QUINOLONE DERIVATIVE; RUFLOXACIN; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE PSYCHOSIS; AGITATION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; BLOOD BRAIN BARRIER; BLOOD DISEASE; CONFUSION; CONVULSION; DELIRIUM; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG SAFETY; GRAND MAL SEIZURE; HEADACHE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INSOMNIA; KIDNEY DISEASE; MANIA; MEDLINE; METABOLIC DISORDER; MYOCLONUS; NAUSEA; NEUROTOXICITY; OUTPATIENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; QUINOLONES;

EID: 79956071542     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11587280-000000000-00000     Document Type: Review

References (127)

1. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41: 1859-66 (Pubitemid 350044349)
2. Zhanel GH, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001; 1 (5): 459-63 (Pubitemid 33593833)
3. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Oph-thalmol 2004; 49 Suppl. 2: S73-8
4. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005; 4 (2): 299-309 (Pubitemid 40867340)
5. Lewis RJ, Mohr III JF. Dysglycaemias and fluoroquinolones. Drug Saf 2008; 31 (4): 283-92 (Pubitemid 351441577)
6. Dukes MNG, editor. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: fluoroquinolones. 15th ed. Amsterdam: Elsevier Science, 2006: 1396-407
7. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003; 5 Suppl. 3: S29-36 (Pubitemid 38195639)
8. Smith DA, Schmid EF. Drugs withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006; 9 (1): 38-46
9. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47 Suppl. 3: 3-8
10. European Medicines Agency. EMEA restricts use of oral norfloxacin drugs in UTIs. London: European Medicines Agency, 2008 Jul 24
11. European Medicines Agency (EMEA), Danish Medicines Agency. EMEA recommends restricting the use of oral moxifloxacin-containing medicines. London: European Medicines Agency, 2008 Jul 24
12. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl. 2: S144-57 (Pubitemid 40962485)
13. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253-72S
14. Sweetman SC, editor. Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press; 2002: 113, 182-6, 201, 209, 219-20, 232; 248, 266-7
15. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51 Suppl. 1: 21-7 (Pubitemid 36622101)
16. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21 (10 Pt 2): 233-52S
17. Perry CM, Barman Balfour JA, Lamb HM. Gatifloxacin. Drugs 1999 Oct; 58 (4): 683-96; discussion 697-8 (Pubitemid 29520514)
18. Jo M, Tachi N, Shinoda M. Convulsions from excessive dosage of nalidixic acid: a case report. Brain Dev 1979; 1: 327-9 (Pubitemid 10085092)
19. Koppel C, Hopfe T, Menzel J. Central anticholinergic syndrome after ofloxacin overdose and therapeutic doses of diphenhydramine and chlormezanone. J Toxicol Clin Toxicol 1990; 28: 249-53 (Pubitemid 20293780)
20. Bagon JA. Neuropsychiatric complications following quinolone overdose in renal failure [letter]. Nephrol Dial Transpl 1999; 14: 1337 (Pubitemid 29209348)
21. Tattevin P, Messiaen T, Pras V, et al. Confusion and general seizures following ciprofloxacin administration. Ne-phrol Dial Transplant 1998; 13: 2712-3 (Pubitemid 28445914)
22. Aoun M, Jacquy C, Debusscher L, et al. Peripheral neuropathy associated with fluoroquinolones [letter]. Lancet 1992; 340: 127
23. Oron JD, Ivorra J, Portilla J, et al. Reaccion psicotica tras la administracion de indometacina y ciprofloxacino [let-ter]. Rev Clin Esp 1992; 191: 401 (Pubitemid 23013286)
24. Altes J, Gasco J, Antonio J, et al. Ciprofloxacin and delirium. Ann Intern Med 1989; 110: 170-1
25. McDermott JL, Gideonse N, Campbell JW. Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient. J Am Geriatr Soc 1991; 39: 909-10
26. Kiangkitiwan B. Levofloxacin-induced delirium with psychotic features. Gen Hosp Psychiatry 2008; 30 (4): 381-3 (Pubitemid 351862308)
27. Reeves RR. Ciprofloxacin-induced psychosis. Ann Pharmacother 1992; 26: 930-1
28. Meher LK, Tripathy D, Acharya S. Ciprofloxacin induced psychosis. J Assoc Physicians India 1992; 40: 418-9
29. Mulhall JP, Bergmann LS. Ciprofloxacin-induced acute psychosis. Urology 1995; 46 (1): 102-3
30. Zaudig M, von Bose M, Weber MM, et al. Psychotoxic effects of ofloxacin. Pharmacopsychiatry 1989; 22: 11-5 (Pubitemid 19053579)
31. James E, Demian A. Acute psychosis in a trauma patient due to ciprofloxacin. Postgrad Med J 1998; 74: 189-90 (Pubitemid 28132410)
32. Hakko E, Mete B, Ozaras R, et al. Levofloxacin-induced delirium [letter]. Clin Neurol Neurosurg 2005; 107 (2): 158-9
33. Andrejak M, Schmit JL, Tondriaux A, et al. Neurological side effects of fluoroquinolones: apropos of 9 cases concerning pefloxacin [in French]. Therapie 1992; 47 (5): 415-8
34. Asensio-Sanchez VM, Rodriguez-Delgado B, Garcia-Herrero E, et al. Visual hallucinations secondary to ciprofloxacin treatment. Arch Soc Esp Oftalmol 2007; 82 (5): 299-301
35. Melvani S, Speed BR. Alatrofloxacin-induced seizures during slow intravenous infusion. Ann Pharmacother 2000; 34: 1017-9 (Pubitemid 30660778)
36. Quigley CA, Lederman JR. Possible gatifloxacin-induced seizure. Ann Pharmacother 2004; 38: 235-7 (Pubitemid 38112233)
37. Isaacson SH, Carr J, Rowan AJ. Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state. Neurology 1993; 43: 1619-21 (Pubitemid 23230562)
38. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998; 20 (6): 1049-70 (Pubitemid 29058410)
39. Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999 Mar; 57 (3): 363-73; discussion 374
40. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem 2001; 8 (4): 371-84 (Pubitemid 32409786)
41. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35 (10): 1194-8 (Pubitemid 32959185)
42. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002;65(3)455-64. (Pubitemid 34174022)
43. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29-36
44. Tamai I, Yamashita J, Kido Y, et al. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 2000; 295 (1): 146-52
45. Mandell L, Tillotson G. Safety of fluoroquinolones: an update. Can J Infect Dis 2002; 13 (1): 54-61 (Pubitemid 34453830)
46. Case report [online]. Available from URL: http://en.wiki pedia.org/wiki/Case-report [Accessed 2010 Sep 8]
47. ICH E2E: pharmacovigilance planning. CPMP/ICH/5716/03 [online]. Available from URL: http://www.ich. org/products/guidelines/efficacy/article/efficacy- guidelines. html [Accessed 2010 Sep 8]
48. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30 (5): 367-73 (Pubitemid 46740334)
49. Tripathi A, Chen SI, O'Sullivan S. Acute psychosis following the use of topical ciprofloxacin. Arch Ophthalmol 2002; 120: 665-6 (Pubitemid 34496629)
50. Orr CF, Rowe DB. Eardrops attacks: seizures triggered by ciprofloxacin eardrops. Med J Aust 2003; 178: 343 (Pubitemid 36503099)
51. Islam MA, Sreedharan T. Convulsions, hyperglycemia and glycosuria from overdose of nalidixic acid. JAMA 1965; 192: 1100-1
52. Schwartz MT, Calvert JF. Potential neurological toxicity related to ciprofloxacin. DICP 1990; 24 (2): 138-40 (Pubitemid 20105794)
53. Kim SH, Jeong SH, Kim JW, et al. A case of hemiballism as a rare side effect of ciprofloxacin in a patient with liver cirrhosis. Chemotherapy 2009; 55: 207-10
54. Holden R. Probable fatal interaction between ciprofloxacin and theophylline [letter]. BMJ 1988; 297: 1339
55. Spivey JM, Laughlin PH, Goss TF, et al. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 1991; 20: 1131-4
56. Herrlin K, Segerdahl M, Gustafsson LL, et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356: 2069-70 (Pubitemid 32009827)
57. Fan-Havard P, Sanchorawala V, Oh J, et al. Concurrent use of foscarnet and ciprofloxacin may increase the pro-pensity for seizures. Ann Pharmacother 1994; 28: 869-72 (Pubitemid 24262650)
58. Rollof J, Vinge E. Neurological adverse effects during concomitant treatment with ciprofloxacin, NSAIDs, and chloroquine: possible drug interaction. Ann Pharmacother 1993; 27: 1058-9 (Pubitemid 23293418)
59. Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine [letter]. Psychosomatics 2009; 50 (6): 638-9
60. Sharma DD, Aggarwal A, Sharma RC, et al. A probable association of acute dystonia with gemifloxacin adminis-tration. Indian J Med Sci 2009; 63 (12): 557-60
61. Christie MJ, Wong K, Ting RH, et al. Generalized seizure and toxic epidermal necrolysis following levofloxacin ex-posure. Ann Pharmacother 2005; 39 (5): 953-5 (Pubitemid 40570677)
62. Simpson KJ, Brodie JR. Convulsions related to enoxacin [letter]. Lancet 1985; II: 161
63. Poe TE, Marion GS, Jackson DS. Seizures due to nalidixic acid therapy. South Med J 1984; 77: 539-40 (Pubitemid 14144965)
64. Anastasio GD, Menscer D, Little JM. Norfloxacin and seizures [letter]. Ann Intern Med 1988; 109: 169-70
65. Traeger SM, Nonfiglio MF, Wilson JA, et al. Seizures associated with ofloxacin therapy. Clin Infect Dis 1995; 21 (6): 1504-6 (Pubitemid 26066652)
66. Montane E, Barriocanal A, Isern I, et al. Multiple drug interactions-induced serotonin syndrome: a case report. J Clin Pharm Ther 2009; 34: 485-7
67. Conri C, Lartigue MC, Abs L, et al. Convulsions chez une malade traitee par pefloxacine et theophylline [letter]. Therapie 1990; 45: 358 (Pubitemid 20196147)
68. Bader MB. Role of ciprofloxacin in fatal seizures. Chest 1992; 101: 883-4
69. Romano C, Cristina T, Daniela C, et al. Epileptic attacks associated with pefloxacin treatment in a patient on CAPD [letter]. Clin Nephrol 1989; 32: 48-9 (Pubitemid 19192104)
70. Bercault N, DeMasure M, Benhamou CL, et al. Seizures in the course of prolonged treatment with ofloxacin. Rev Med Interne 1993; 14: 194
71. Slavich IL, Gleffe RF, Haas EJ. Grand mal epileptic seizures during ciprofloxacin therapy. JAMA 1989; 261: 558-9 (Pubitemid 19033865)
72. Karki SD, Bentley DW, Raghavan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP 1990; 24 (6): 595-6 (Pubitemid 20189005)
73. Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J 1991; 84: 465-8
74. Abouesh A, Stone C, Hobbs WR. Antimicrobial-induced mania (antibiomania): a review of spontaneous reports. J Clin Psychopharmacol 2002; 22: 71-81 (Pubitemid 34103001)
75. Lucet JC, Tilly J, Lerebours G, et al. Neurological toxicity related to pefloxacin [letter]. J Antimicrob Chemother 1988; 21: 811-2
76. Walton GD, Hon JK, Mulpur TG. Ofloxacin-induced seizures. Ann Pharmacother 1997; 31 (12): 1475-7
77. Jeandel C, Laurain MC, Jouanny P, et al. Etat de mal epileptique sous ofloxacine. Rev Med Interne 1994; 15: 218-9 (Pubitemid 24105913)
78. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluor-oquinolone consumption data from three Italian regions. Drug Saf 2003; 26 (2): 109-20 (Pubitemid 36188561)
79. Halliwell RF, Su J, Demuro A, et al. Characterization of the interaction between a novel convulsant agent, norbi-phen, and GABAA and other ligand-gated ion channels. Neuropharmacology 2002; 43: 778-87 (Pubitemid 35279584)
80. Shimada J, Hori S. Adverse effects of fluoroquinolones. Prog Drug Res 1992; 38: 133-43
81. Kim J, Ohtani H, Tsujimoto M, et al. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal anti-inflammatory agents. Drug Metab Pharmacokinet 2009; 24 (2): 167-74
82. Marinella MA. Myoclonus and generalized seizures associated with gatifloxacin treatment. Arch Intern Med 2001; 161: 2261-2 (Pubitemid 32905010)
83. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20 (4): 289-302 (Pubitemid 36403432)
84. Lahmek P, Michel L, Meunier N, et al. A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence. Case Report Med. Epub 2010 Jan 24
85. Agbaht K, Bitik B, Piskinpasa S, et al. Ciprofloxacinassociated seizures in a patient with underlying thyrotox-icosis: case report and literature review. Int J Clin Pharmacol Ther 2009; 47 (5): 303-10
86. Hall CE, Keegan H, Rogstad KE. Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. Int J STD AIDS 2003; 14 (9): 636-7 (Pubitemid 37072184)
87. McCue JD, Zandt JR. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med 1991; 90 (4): 528-9
88. Grimm O, Alm B, Fur Seelische Z. A case of ciprofloxacininduced acute polymorphic psychosis with a distinct def-icit in executive functions [letter]. Psychosomatics 2007; 48 (3): 269 (Pubitemid 46769634)
89. Norra C, Skobel E, Breuer C, et al. Ciprofloxacin-induced acute psychosis in a patient with multidrug-resistant tuberculosis. Eur Psychiatry 2003; 18 (5): 262-3 (Pubitemid 37010321)
90. Farrington J, Stoudemire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiolo-gies. Gen Hosp Psychiatry 1995; 17: 47-53
91. Fennig S, Mauas L. Ofloxacin-induced delirium [letter]. J Clin Psychiatry 1992; 53 (4): 137-8
92. Ahuja N, Lloyd AJ. Antibiomania and ciprofloxacininduced mania [letter]. Psychosomatics 2007; 48 (4): 36
93. de Bazignan AD, Thiessard F, Miremont-Salame G, et al. Psychiatric adverse effects of fluoroquinolones: review of cases from the French pharmacologic surveillance data-base. Rev Med Interne 2006; 27 (6): 448-52
94. Steinert T, Studemund H. Acute delusional parasitosis under treatment with ciprofloxacin. Pharmacopsychiatry 2006; 39 (4): 159-60 (Pubitemid 44199187)
95. Cheung YF, Wong WW, Tang KW, et al. Ciprofloxacininduced palatal tremor. Mov Disord 2007; 22 (7): 1038-43
96. Lee CH, Cheung RTF, Chan TM. Ciprofloxacin-induced oral facial dyskinesia in a patient with normal liver and renal function. Hosp Med 2000; 61: 142-3
97. Azar S, Ramjiani A, Van Gerpen JA. Ciprofloxacininduced chorea. Mov Disord 2005; 20: 513-4
98. Pastor P, Moitinho E, Elizalde I, et al. Reversible oralfacial dyskinesia in a patient receiving ciprofloxacin hydrochloride. J Neurol 1996; 243: 616-7 (Pubitemid 26265832)
99. MacLeod W. Case report: severe neurological reaction to ciprofloxacin. Can Fam Physician 2001; 47: 553-5 (Pubitemid 32268218)
100. Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother 1996; 30: 138-41 (Pubitemid 26066677)
101. Post B, Koelman JHTM, Tijssen MAJ. Propriospinal myoclonus after treatment with ciprofloxacin. Mov Dis-ord 2004; 19: 595-7
102. Mohan N, Menon K, Rao PG. Oral gatifloxacin-induced ataxia [letter]. Am J Health Syst Pharm 2002; 59 (19): 1894
103. Rosolen A, Drigo P, Zanesco L. Acute hemiparesis associated with ciprofloxacin [letter]. BMJ 1994; 309: 1411 (Pubitemid 24351409)
104. Upton C. Sleep disturbance in children treated with ofloxacin [letter]. BMJ 1994; 309: 141
105. Akhtar S, Ahmad H. Ciprofloxacin-induced catatonia [letter]. J Clin Psychiatry 1993; 54: 115-6
106. Youssef NA, Benazzi F, Desan PH. Levofloxacin-induced catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (4): 741-2
107. Rauser EH, Ariano ER, Anderson AD. Exacerbation of myasthenia gravis by norfloxacin. DCIP Ann Pharmacother 1990; 240: 207-8 (Pubitemid 20105811)
108. Mumford CJ, Ginsberg L. Ciprofloxacin and myasthenia gravis [letter]. BMJ 1990; 301: 818
109. Fraser AG, Harrower ADB. Convulsions and hyperglycaemia associated with nalidixic acid [letter]. BMJ 1977; 2 (6101): 1578
110. Striano P, Zara F, Coppola A, et al. Epileptic myoclonus as ciprofloxacin-associated adverse effect. Mov Disord 2007; 22 (11): 1675-6 (Pubitemid 47477944)
111. Bellon A, Perez-Garcia G, Coverdale JH, et al. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol2009; 65 (10): 959-62
112. Kisa C, Yildirim SG, Aydemir C, et al. Prolonged electroconvulsive therapy seizure in a patient taking ciprofloxacin. J ECT 2005; 21 (1): 43-4 (Pubitemid 40471326)
113. LaSalvia EA, Domek GJ, Gitlin DF. Fluoroquinoloneinduced suicidal ideation. Gen Hosp Psychiatry 2010 Jan-Feb; 32(1): 108-10
114. Sire S, Staub-Schmidt T, Ragnaud JM, et al. Aprposd'une crise comitiale sous of loxacine. Rev Med Interne 1996; 17: 601-2 (Pubitemid 26253504)
115. Barrett MJ, Login IS. Gemifloxacin-associated neurotoxicity presenting as encephalopathy. Ann Pharmacother 2009; 43 (4): 782-4
116. Heyd A, HaverstockD. Retrospective analysis of thesafety profile of oral and intravenous ciprofloxacin in a geriatric population. Clin Ther 2000; 22 (10): 1239-50
117. Bertino Jr J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22 (7): 798-817 (Pubitemid 30625913)
118. Stahlmann R, LodeH. Toxicity of quinolones. Drugs 1999; 58 Suppl. 2: 37-42 (Pubitemid 29500083)
119. Cipro®: summary of product characteristics. Wayne (NJ): Bayer Healthcare Pharmaceuticals Inc. 2009
120. Tavanic® 500mg tablets: summary of product characteristics. Guildford: Sanofi-Aventis, 2009
121. Seizure: causes [online]. Available from URL: http://en.wikipedia.org/ wiki/Seizure#Causes [Accessed 2010 Feb 15]
122. Akaike N, Shirasaki T, Yakushiji T. Quinolone and fenbufen interact with GABA(A) receptor in dissociated hippo-campal cells of rat J Neuropsychol1991; 66 (2): 497-504
123. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41 (4): 277-84 (Pubitemid 26114816)
124. Sweweb [online]. Available from: URL: http://sweweb. mpa.se/swedisii/ [Accessed 2010 Feb 15]
125. Utinor® tablets 400 mg: summary of product characteristics. Whitehouse Station (NJ): Merck Sharp & Dohme Limited, 2009
126. Tarivid® 200 mg and 400mg tablets: summary of product characteristics. Guildford: Sanofi-Aventis, 2009
127. US FDA. Risk of fluoroquinolone-associated myasthenia gravis exacerbation February 2011 label changes for fluoroquinolones [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm 247115.htm2011 [Accessed 2011 Apr 18]